NO20053846L - Fremgangsmate for a modifisere legemiddel-krystalldannelse - Google Patents

Fremgangsmate for a modifisere legemiddel-krystalldannelse

Info

Publication number
NO20053846L
NO20053846L NO20053846A NO20053846A NO20053846L NO 20053846 L NO20053846 L NO 20053846L NO 20053846 A NO20053846 A NO 20053846A NO 20053846 A NO20053846 A NO 20053846A NO 20053846 L NO20053846 L NO 20053846L
Authority
NO
Norway
Prior art keywords
crystal formation
drug crystal
modifying drug
modifying
crystals
Prior art date
Application number
NO20053846A
Other languages
English (en)
Inventor
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053846(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20053846L publication Critical patent/NO20053846L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)

Abstract

Det er beskrevet en fremgangsmåte for å modifisere krystalltilstanden av aciculære legemiddelstoffer, krystaller oppnådd ved en slik fremgangsmåte og spesielle krystallformer eller modifikasjoner av mycofenolsyre eller mycofenolatnatrium, så vel som farmasøytiske preparater omfattende krystallene, fremgangsmåter for behandling og anvendelse derav.
NO20053846A 2003-01-20 2005-08-16 Fremgangsmate for a modifisere legemiddel-krystalldannelse NO20053846L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0301259.8A GB0301259D0 (en) 2003-01-20 2003-01-20 Organic compounds
PCT/EP2004/000354 WO2004064806A2 (en) 2003-01-20 2004-01-19 Process for modifying drug crystal formation

Publications (1)

Publication Number Publication Date
NO20053846L true NO20053846L (no) 2005-08-16

Family

ID=9951448

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053846A NO20053846L (no) 2003-01-20 2005-08-16 Fremgangsmate for a modifisere legemiddel-krystalldannelse

Country Status (31)

Country Link
US (3) US20060122265A1 (no)
EP (2) EP2308471A1 (no)
JP (1) JP4549976B2 (no)
KR (5) KR20100120321A (no)
CN (2) CN101333201A (no)
AR (2) AR043343A1 (no)
AT (1) ATE546132T1 (no)
AU (1) AU2004206731B2 (no)
BR (1) BRPI0406827A (no)
CA (2) CA2706900A1 (no)
CL (1) CL2004000073A1 (no)
CO (1) CO5580738A2 (no)
CY (1) CY1112772T1 (no)
DK (1) DK1592401T3 (no)
EC (1) ECSP055918A (no)
ES (1) ES2382035T3 (no)
GB (1) GB0301259D0 (no)
IL (1) IL169484A (no)
MX (1) MXPA05007691A (no)
MY (1) MY148297A (no)
NO (1) NO20053846L (no)
NZ (1) NZ541073A (no)
PE (2) PE20110276A1 (no)
PL (2) PL376525A1 (no)
PT (1) PT1592401E (no)
RU (1) RU2388757C2 (no)
SG (1) SG155046A1 (no)
SI (1) SI1592401T1 (no)
TW (1) TWI325785B (no)
WO (1) WO2004064806A2 (no)
ZA (1) ZA200504442B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
WO2005105768A2 (en) 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es) 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
TWI322147B (en) 2004-07-20 2010-03-21 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
PL2349220T3 (pl) * 2008-10-09 2012-12-31 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Zastosowanie rozpuszczalników organicznych w granulacji na mokro moksyfloksacyny
CN101756958B (zh) * 2008-11-10 2011-07-20 鲁南制药集团股份有限公司 一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
JP5658751B2 (ja) 2009-07-10 2015-01-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ １−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼンのための結晶化方法
EA201270544A1 (ru) * 2009-10-13 2012-09-28 Тева Фармасьютикал Индастриз Лтд. Композиции с отсроченным высвобождением
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
NZ703128A (en) 2010-05-11 2016-04-29 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
WO2012140120A1 (en) 2011-04-13 2012-10-18 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
LT3394051T (lt) * 2015-12-21 2020-08-10 Janssen Pharmaceutica N.V. Kristalizacijos procedūra, skirta kanagliflozino hemihidrato kristalų gavimui
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
KR20190113955A (ko) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN108727317A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 一种麦考酚酸的晶型物
CN108727318A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 麦考酚酸的晶型物
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法
CN110922371B (zh) * 2019-12-27 2020-08-11 广东蓝宝制药有限公司 一种m2晶型麦考酚钠的制备方法
CN120168469A (zh) 2020-05-18 2025-06-20 诺华股份有限公司 Lnp023的结晶形式
US20250296904A1 (en) * 2022-05-31 2025-09-25 Honshu Chemical Industry Co., Ltd. Crystal of 4,4'-bis(1,1-bis(4-hydroxy-3-methylphenyl)ethyl)biphenyl and method for producing the same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158835A (en) * 1875-01-19 Improvement in mortising-tools
GB935432A (en) * 1958-05-29 1963-08-28 Secr Aviation Improvements in the manufacture of crystalline substances
US3187039A (en) * 1962-10-19 1965-06-01 Commercial Solvents Corp Method for changing the crystal habit of monosodium glutamate
US3183263A (en) * 1962-10-19 1965-05-11 Commercial Solvents Corp Method for changing the crystal habit of mono-sodium glutamate
US3352906A (en) * 1963-02-04 1967-11-14 Charles R Parkerson Habit modification and preparation of single crystal triglycine sulfate
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
US3770390A (en) * 1971-02-26 1973-11-06 Dow Chemical Co Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) * 1980-04-21 1981-03-31 Allied Chemical Corporation Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en) 1980-06-08 1983-11-30 Yeda Res & Dev Resolution of amino acids
JPS5875194A (ja) * 1981-10-30 1983-05-06 株式会社日立製作所 マトリクス表示装置及び駆動方法
JPS59232916A (ja) * 1983-06-16 1984-12-27 Shiraishi Chuo Kenkyusho:Kk 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en) 1985-11-12 1995-12-08 Yeda Res & Dev Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja) 1987-12-25 1995-05-17 東レ株式会社 有機化合物結晶の製造方法
EP0582452B1 (en) * 1992-08-04 1998-10-14 Toda Kogyo Corp. Granulated particles for magnetic particles for magnetic recording and process for producing the same
BR9407469A (pt) 1993-09-15 1996-11-12 Syntex Inc Micofenolato mofetil anidro cristalino e formulação intravenosa do mesmo
JPH09209297A (ja) * 1996-01-26 1997-08-12 Nippon Paper Ind Co Ltd 艶消し軽量塗工紙及びその製造方法
KR100491274B1 (ko) * 1996-04-12 2005-09-05 노파르티스 아게 미코페놀레이트의장용코팅된약제조성물
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
HK1084874A1 (en) 2006-08-11
ES2382035T3 (es) 2012-06-04
BRPI0406827A (pt) 2005-12-27
KR100855149B1 (ko) 2008-08-28
CN100595199C (zh) 2010-03-24
CN101333201A (zh) 2008-12-31
US8124795B2 (en) 2012-02-28
US20110288313A1 (en) 2011-11-24
CO5580738A2 (es) 2005-11-30
GB0301259D0 (en) 2003-02-19
SI1592401T1 (sl) 2012-05-31
PT1592401E (pt) 2012-05-10
TWI325785B (en) 2010-06-11
MXPA05007691A (es) 2005-09-30
ZA200504442B (en) 2006-02-22
EP1592401A2 (en) 2005-11-09
CY1112772T1 (el) 2016-02-10
PE20110276A1 (es) 2011-05-27
CN1738605A (zh) 2006-02-22
MY148297A (en) 2013-03-29
AR103711A2 (es) 2017-05-31
WO2004064806A3 (en) 2004-10-28
CL2004000073A1 (es) 2005-01-14
RU2388757C2 (ru) 2010-05-10
JP4549976B2 (ja) 2010-09-22
AU2004206731A8 (en) 2004-08-05
JP2006515016A (ja) 2006-05-18
EP2308471A1 (en) 2011-04-13
PL213192B1 (pl) 2013-01-31
ATE546132T1 (de) 2012-03-15
AU2004206731B2 (en) 2008-03-20
EP1592401B1 (en) 2012-02-22
PE20040826A1 (es) 2004-12-23
US20060122265A1 (en) 2006-06-08
KR20050096940A (ko) 2005-10-06
RU2005126328A (ru) 2006-07-27
KR20070087181A (ko) 2007-08-27
IL169484A (en) 2016-03-31
CA2509796A1 (en) 2004-08-05
WO2004064806A2 (en) 2004-08-05
PL376525A1 (pl) 2006-01-09
TW200505505A (en) 2005-02-16
US20090209639A1 (en) 2009-08-20
KR20100120321A (ko) 2010-11-15
US8008511B2 (en) 2011-08-30
ECSP055918A (es) 2005-11-22
KR20090115898A (ko) 2009-11-09
PL393385A1 (pl) 2011-03-14
CA2706900A1 (en) 2004-08-05
AU2004206731A1 (en) 2004-08-05
KR20090115821A (ko) 2009-11-06
DK1592401T3 (da) 2012-05-21
CA2509796C (en) 2010-09-14
SG155046A1 (en) 2009-09-30
IL169484A0 (en) 2007-07-04
AR043343A1 (es) 2005-07-27
NZ541073A (en) 2008-12-24
KR101129105B1 (ko) 2012-04-12

Similar Documents

Publication Publication Date Title
SG155046A1 (en) Process for modifying drug crystal formation
NO20074012L (no) 1-tio-D-glucitolderivater
NO20055219L (no) Nye forbindelser
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
BRPI0315296B8 (pt) derivados do ciclohexanol espirocíclicos, medicamento incluindo pelo menos um derivado do ciclohexano espirocíclico e uso de um derivado do ciclohexano espirocíclico
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
NO20074390L (no) Forsterket bimatoprost oye-opplosning
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
BRPI0513824A (pt) derivados glucitol, seu pró-fármaco e seu sal e agente terapêutico contendo os mesmos para diabetes
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
NO20063928L (no) Substituerte kinolinforbindelser
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20065926L (no) Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav
NO20053467L (no) Fremgangsmate ved biotransformasjon av kolkionforbindelser til de tilsvarende 3-glykosyl-derivater
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO20082727L (no) Salter av 9-oksoakridin-10-eddiksyre med 1-alkylamino-1-deoksypolyoler
NO20072668L (no) Ny kombinasjon
NO20062450L (no) Analgesiske suspensjoner med kontrollert frigivelse
NO20073772L (no) Preparater som omfatter et epotilon, og fremstillingsfremgangsmate
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
NO20062442L (no) Analgesiske suspensjoner md kontrollert frigivelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application